Transparency Market Research Reports

Website: http://www.transparencymarketresearch.com/

Visit : http://tmrmarketreports.wordpress.com/

Tuesday 30 December 2014

Anxiety Disorders and Depression Treatment Market Growth 2014 - 2020

The global anxiety disorders and depression treatment market was valued at USD 22.5 billion in 2013 and is expected to reach USD 18.2 billion in 2020, at a CAGR of (1.25%) from 2014 to 2020.

Browse Anxiety Disorders and Depression Treatment Market Report with Full TOC at http://www.transparencymarketresearch.com/anxiety-disorders-depression-treatments.html

Anxiety is a biological reaction to stress, trauma and fear, which can be experienced by anyone in their lifetime, whereas depression is a mental state of low mood and aversion to daily activities that can affect an individual’s feelings, thoughts, sense of well-being and behavior. Depression affects 10% to 15% men and about 10% to 25% women. According to the World Health Organization (WHO), to date, over 350 million people have been affected by depression globally. The Anxiety and Depression Association of America revealed that at present approximately 40 million people in the U.S. are suffering from anxiety disorder and treating these patients costs around USD 42 billion each year. Thus, high prevalence of anxiety disorders and depression helped the market to transform itself into a billion dollar industry. However, the current scenario indicates that the overall anxiety disorders and depression treatment market would decline due to patent expiry of major antidepressants, weak pipeline of novel drugs and increasing number of generic drug variants.

The anxiety disorders and depression treatment market has been segmented based on the drug classes commonly used for the treatment of various types of anxiety disorders and depression such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tetracyclic antidepressants (TeCA), monoamine oxidase inhibitors (MAOIs), benzodiazepines, atypical antipsychotics, anticonvulsants and beta blockers. SNRIs accounted for the largest share of over 30% of the depression treatment market in 2013. However, the segment is expected to witness a decline in revenue in the near future, reporting a CAGR of 14.2% from 2012 to 2016 and a CAGR of 4.3% from 2016 to 2020. Increasing influx of generic formulations as well as patent expiry of leading branded formulations such as Cymbalta, Lexapro and Effexor XR are some of the major factors that would negatively affect the growth of the segment. Moreover, with the loss of patent exclusivity, generics would offer physicians a broad range of affordable medications to prescribe, thereby significantly reducing the overall size of the anxiety disorders and depression treatment market. Hence, the future growth of the market would depend on commercialization of novel drugs for new indications.

Major pipeline drugs identified and expected to be launched during the forecast period from 2014 to 2020 include Brintellix [(Vortioxetine-Lu AA21004) (Lundbeck and Takeda)], Brexpiprazole [(OPC-34712) (Otsuka)] and ALKS-5461 [(FDC-buprenorphine and samidorphan) (Alkermes plc)]. The positive clinical trial outcomes of these drugs and anticipated commercialization during the forecast period are expected to fuel the growth of antidepressants and anxiolytic drugs market in the near future.

Request for customization of this report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1199

Geographically, North America accounted for the largest share of the anxiety disorders and depression treatment market in 2013 (over 35%). The U.S. accounted for the highest share of the revenue for each drug class due to the presence of one or more branded formulations that influenced the market dynamics significantly. However, the anxiety disorders and depression treatment market in the U.S. is currently saturated due to the presence of cheap generic products and several antidepressant drugs available on prescription for the same indication. Hence, the region is expected to witness a negative CAGR throughout the forecast period from 2014 to 2020. Asia Pacific is estimated to witness an appreciable growth rate (0.02%) due to various factors such as positive marketing approval for novel medicines, growing geriatric population and presence of a large population base in the region. Additionally, strong economic growth in countries such as China, Japan, New Zealand and Australia would contribute to the growth of the market in Asia Pacific.

The market displays intense competitive rivalry among existing players, as currently the market for antidepressant and anxiolytic drugs is highly fragmented comprising both large and small manufacturers. Major market players include AstraZeneca plc, Eli Lilly and Company, Forest Laboratories, Inc., H. Lundbeck A/S, GlaxoSmithKline plc, Johnson & Johnson and Merck & Co., Inc. Eli Lilly and Company held the largest share of over 30% of the total anxiety disorders and depression treatment market in 2013. Product efficacy, differentiation, safety, well-developed distribution networks, and supply capabilities played a major role in determining the market position of the company.

Browse press Release Anxiety Disorders and Depression Treatment Market http://www.transparencymarketresearch.com/pressrelease/anxiety-disorders-depression-treatments.htm

Browse the full Anxiety Disorders and Depression Treatment Market [Drug Classes: SSRIs, SNRIs, Benzodiazepines, Beta Blockers, TCAs, TeCAs, Atypical Antipsychotics, Anticonvulsants and MAOIs] - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 report at http://www.transparencymarketresearch.com/anxiety-disorders-depression-treatments.html

The global anxiety disorders and depression treatment market has been segmented as follows:

Anxiety Disorders and Depression Treatment Market, by Drug Class

Selective Serotonin Reuptake Inhibitors (SSRIs)
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Atypical Antipsychotics
Tricyclic Antidepressants (TCAs)
Tetracyclic Antidepressants (TeCAs)
Monoamine Oxidase inhibitors (MAOIs)
Benzodiazepines
Beta-Blockers
Anticonvulsants

Anxiety Disorders and Depression Treatment Market, by Geography

North America
Europe
Asia-Pacific
Rest of the World (RoW)

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Contact

Sheela AK

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Hospital Pharmaceuticals Market Segment Forecasts up to 2020, Research Reports

The global hospital pharmaceuticals market was valued at USD 26.5 billion in 2013 and is estimated to reach USD 11.6 billion by 2020 declining with a CAGR of (10.5)% from 2014 to 2020.

The report defines hospital pharmaceuticals as drugs that are exclusively administered in hospital and professional healthcare facilities that encompass both in-patient as well as out-patient departments. Hospital pharmaceuticals market which had been experiencing slumps in past three to four years due to economic slowdown, patent and exclusivity loss of various orphan and blockbuster drugs is expected to recover at a rapid pace. Over a decade there has been a considerable rise in several chronic disorders that can only be treated in hospital setting such as renal failure, canter, stroke, Alzheimer's disease and angina which is expected to boost hospital pharmaceuticals market in forthcoming years.

Browse the full Hospital Pharmaceuticals Market: http://www.transparencymarketresearch.com/hospital-pharmaceuticals-market.html

According to World Health Organization (WHO), coronary heart diseases across the globe accounts for over 7.5 million mortalities annually. Moreover as per an analysis by Centers for Disease Control and Prevention (CDC), each year stroke kills approximately 130,000 Americans of which about 87% of them are ischemic strokes. Approximately 5.1 million people in the United States suffered from heart failure in 2013. The aforementioned statistics clearly depict the latent potential for growth owing to substantial rise in various disease indications which in last two years accounted for major source of revenue for hospital pharmacies.

The report studies the hospital pharmaceuticals market from two perspectives: major therapeutic class and indications. Market by therapeutic class includes all major drug classes that are majorly prescribed and sold in hospital pharmacies. Market by indication is segmented into six major disorders: cardiology, oncology, nephrology and urology, neurology, pain and anti-infectives. Among the mentioned indications, oncology and cardiology are key markets share declining at a CAGR of (13.01)% and (9.38)% respectively. Decline in growth rate for both the markets is majorly attributed to increasing number of drugs losing their exclusivity during the forecast period (2014-2020). Billion dollar cardiovascular medicines that are getting off patent include Exforge HCT (amlodipine/hydrochlorothiazide/valsartan), Benicar HCT (hydrochlorothiazide and olmesartan) and VESIcare (Solifenacin Succinate) in 2014, 2016 and 2018 respectively. Furthermore various billion dollar oncology drugs which will get off patent in next 5 years comprise Gleevec (Imatinib Mesylate), Tarceva (erlotinib), Zytiga (Abiraterone Acetate) and Velcade (bortezomib).

Request for customization of this report http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3535

Rise in emergency department visits and increased per capita spending of patients across the globe are some of the major drivers escalating the growth of the overall market. Emergency department visits accounted for 7.4% of the total hospital visits in the U.S. in 2011 compared to 2.3% in 2010. Healthcare Cost and Utilization Project (HCUP) statistical brief data estimated that emergency department discharges increased five times (359 patients per 1,000 people) in the U.S. in 2011 compared to 2010. A large number of new molecular entities are also anticipated to be launched during the forecast period. These primarily include therapeutic areas such as cancer, neurological disorders, infections and cardiovascular diseases. All these factors would increase the global spending on medicines. Moreover, global spending on medicines is expected to increase from USD 1 trillion in 2014 to USD 1.2 trillion by 2017. Such factors are expected to boost the market for hospital pharmaceuticals market especially in case of generic drugs.

Browse all Press Releases: http://www.transparencymarketresearch.com/press-releases.htm

Geographically, North America market accounted for the largest share in 2013 due to 2013 due to favorable reimbursement policies, high awareness, rising per capita income, increased spending on the healthcare and greater depth of marketing efforts by key players. Total spending on healthcare in the U.S. increased from USD 320 million in 2012 to USD 330 million in 2013 depicting an increase of per capita spending by 1%. Presence of sound intellectual property in the European Union countries and presence of high quality pharmaceutical research organizations are among the few prominent drivers. Whereas, fragmented pricing system and improper reimbursement scenario and regulatory framework for clinical trials are key restraints to the European hospital pharmaceuticals market. Asia Pacific and Rest of the World are among the fastest growing markets for hospital pharmaceuticals due to the presence of large population base, aging population suffering from chronic diseases and increasing disposable income.

Browse the full press release of Hospital Pharmaceuticals Market: http://www.transparencymarketresearch.com/pressrelease/hospital-pharmaceuticals-market.htm

Leading market players in this market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi -Aventis.

The Global Hospital Pharmaceuticals Market is segmented into the following categories:

Cardiology

Anti-Adrenergic Drugs
Calcium Channel Blockers
Diuretic Drugs
Anti-Arrhythmic Drugs
Others

Oncology

Alkylating Agents
Anti-Metabolites
Hormonal Agents
Immunomodulating Agents
Miscellaneous Drugs

Nephrology and Urology

Diuretic Agents
Anti-Hypertensive Agents
Phosphate Binders
Anticholinergic Drugs
5-Alpha Reductase Inhibitors

Neurology

Anti-Anxiety Agents
Detail2Anti-Migraine Drugs
Antidepressant Drugs
Anti-Psychotic Drugs

Pain

Anticonvulsant Drugs
Anesthetic Drugs
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Opioids
Non-Narcotics Analgesic Drugs

Infection

Antibacterial Drugs
Antiviral Drugs
Antifungal Drugs
Antiparasite Drugs

Global Hospital Pharmaceuticals Market, by Major Indications

Cardiology

Coronary Heart Diseases
Stroke
High Blood Pressure
Heart Failure
Others

Oncology

Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Others

Nephrology and Urology

Acute Kidney Failure
Chronic Kidney Diseases
Glomerular Diseases
Diabetes
Others

Neurology

Epilepsy
Alzheimer;s Disease
Parkinson;s Disease
Multiple Sclerosis
Others

Pain

Neuropathic Pain
Fibromyalgia
Osteoarthritis
Rheumatoid Arthritis
Cancer Pain

Infection

Detail1Tuberculosis
Pneumonia
Hepatitis A
Hepatitis B
Candida Infection
Fungal Meningitis
Shigellosis
Amoebiasis
Other

Global Hospital Pharmaceuticals Market, by Geography

North America
Europe
Asia Pacific
Rest of the World (RoW)

About Us:

Contact:

Sheela AK

State Tower, 90 State Street,

Suite 700, Albany NY - 12207

USA/Canada Toll Free: 866-552-3453

Growth Of Global Camera Module Market 2013 - 2019

The global market of camera modules that the market will grow from a net worth of nearly US$12.00 billion in 2012 to US$43.06 billion by the end of 2019, growing at a healthy CAGR of nearly 19.7% between 2013 and 2019. Rising demands for CMOS camera modules and robust expansion of the market in Asia-Pacific countries such as India, China, Korea, Taiwan, and Singapore are supporting growth of the market. The report is titled “Global Camera Module Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2013 – 2019”. The report states that the global camera module market is primarily driven by the increasing use of these devices and the growing demand for their technologically advanced versions in smartphones and tablet computers and the automotive sector.

Browse the full report with complete TOC at Global Camera Module Market http://www.transparencymarketresearch.com/camera-module-market.html

The report focuses on three major sectors of the global camera module market: type of sensor used in camera modules, chief applications of camera modules in the market, and geographic segmentation of major regional markets of camera modules.

Based on the type of sensor used in them, camera modules are segmented into two chief classes: complementary metal oxide semiconductor (CMOS) camera modules and charge coupled devices (CCD) camera modules. Chief applications of camera modules are found in fields such as defense and space, automotives, consumer electronics, medical science, industrial and security purposes, and most importantly in tablet computers and smartphones.

The segment CMOS camera devices had a clear dominance in market in 2012 when it held more than half the market shares. Application-area wise, the segment smartphones was responsible for more than 80% demand for camera modules in 2012. In the coming years, the rising popularity of smartphones with camera at both ends (rear and front) will allow this market segment to maintain its dominance upon the market. The market segment smartphones is expected to grow at a CAGR of 21.9% between 2013 and 2019, followed by the segment consumer devices (except tablet computers and smartphones).

Request for customization of this report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1683

Countries in the Asia-Pacific region, being host to some of the chief camera modules manufacturers of the globe, are the dominant regional markets of the global camera module market. In 2012, these regions were responsible for nearly 60% revenue shares of the total market. Europe is the second largest market of the global camera module market, and is expected to grow at a CAGR of nearly 19.3% between 2013 and 2019.

The global camera module market is highly fragmented with market players competing hard to acquire significant market shares. Major businesses operating in the global camera modules’ marketplace include SEMCO, Liteon Chicony, Toshiba, STMicro, LG-Innotek, Primax, Sharp, Foxconn, Sunny, Samsung Fiberoptic, BYD, Vista Point, Cowell, Truly, and KMOT.

Browse all Semiconductor & Electronics Market Research Reports @ http://www.transparencymarketresearch.com/semiconductor-market-reports-5.html

About Us

Contact

Sheela AK

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Visit : http://tmrmarketreports.wordpress.com/

Monday 29 December 2014

CINV Existing and Pipeline Drugs Market Segment Forecasts up to 2020, Research Reports

Chemotherapy induced nausea and vomiting (CINV) refers to the nausea and vomiting associated with cancer chemotherapy. Various sources indicate that approximately 70% to 80% cancer patients undergoing chemotherapy exhibit nausea and vomiting as major symptoms. Chemotherapy induced nausea and vomiting is an extremely debilitating condition. Although there are currently a number of drugs available to manage CINV, they do not effectively address the symptoms of this condition.

Browse CINV Existing and Pipeline Drugs Market Report with Full TOC at http://www.transparencymarketresearch.com/cinv-market.html

The report on CINV existing and pipeline drugs market offers an insightful and in-depth assessment of the current as well as future market potential of CINV drugs. Aloxi (palonosetron), Zofran generic (ondansetron), Kytril generic (granisetron), Emend (aprepitant) and Akynzeo (netupitant-palonosetron FDC) are the major currently available drugs extensively studied in the report. The historical market size and forecast for each of these drugs (except for Akynzeo, as the U.S. Food and Drug Administration (FDA) approved it only in October 2014) in terms of revenue (USD Million) has been provided in the report for the period from 2012 to 2020. In addition, the compounded annual growth rate (CAGR) for each of these drugs has been provided in the report for the forecast period from 2014 to 2020, considering 2012 and 2013 as base years. The report also studies the CINV patient pool for each of these drugs. The market size and CAGR for Akynzeo have been determined for the years from 2015 to 2020.

The report also provides extensive analysis of the pipeline drugs SUSTOL (extended release granisetron injection) and rolapitant, including the status of current clinical trials and future sales projection in terms of USD million. The future sales projection of both these pipeline drugs has also been provided for the North American and European regions. The study also provides estimated patient pool for both these pipeline drugs, broken down by North America and Europe.

In this research study, the global market for CINV drugs has been geographically segmented into four regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The CINV drugs market size and forecast in terms of revenue for each region has been provided for the period from 2012 to 2020 along with the CAGR for the forecast period from 2014 to 2020. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities. The market overview chapter provides information such as major subtypes of CINV, the etiology of CINV, the pathogenesis of CINV, major emetogenic chemotherapeutic agents, treatment recommendations for CINV and unmet needs in the CINV market. A section on event impact analysis has also been provided in the market overview chapter of the report on CINV existing and pipeline drugs market.

For further inquiries, click here : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=776

The report on chemotherapy induced nausea and vomiting drugs market also includes a section on the competitive landscape of the market, wherein the qualitative analysis of leading players in the global CINV drugs market is presented. The report concludes with the profiles of major players in the chemotherapy induced nausea and vomiting drugs market such as GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc. and Tesaro, Inc. Each company profile comprises information such as company overview, financial overview (selling, general and administrative expenses, research and development expenses and annual revenue for consecutive three years 2011, 2012 and 2013), current and pipeline product portfolio, business strategies and recent developments.

The global CINV existing and pipeline drugs market is segmented as follows:

CINV Existing and Pipeline Drugs Market Revenue (USD Million), by Major Drugs

Aloxi (palonosetron)
Zofran Generic (ondansetron)
Kytril Generic (granisetron)
Emend (aprepitant)
Akynzeo (netupitant-palonosetron)
SUSTOL (extended release granisetron injection)
Rolapitant

CINV Existing and Pipeline Drugs Market Revenue (USD Million), by Geography

North America
Europe
Asia-Pacific
Rest of the World (RoW)

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us

Contact

Sheela AK

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

High Potency Active Pharmaceutical Ingredients Market Size 2012 - 2018

The global HPAPI market was worth USD 9.1 billion in 2011 and is expected to reach USD 17.5 billion in 2018, growing at a CAGR of 9.9% from 2012 to 2018. In the overall global market, North America accounts for the largest market share, whereas Asia Pacific is likely to witness highest growth in the forecasted period. India and China will be the major countries to register high growth rate in the high potency active pharmaceutical ingredients (HPAPIs) market due to rising health awareness, growing economies and improving healthcare systems.

Browse the full report at High Potency Active Pharmaceutical Ingredients Market http://www.transparencymarketresearch.com/high-potency-active-pharmaceutical-Ingredients-market.html

High potency active pharmaceutical ingredients (HPAPIs) are growing rapidly as compared to other segments of the healthcare industry. HPAPI are the compounds helpful in the treatment of respiratory disorders, treatment of cancer and hormonal imbalances. Growing oncology therapeutics market worldwide is the key factor driving the growth of this market.

High potency active pharmaceutical ingredients market is a growing concept and is considered to be a boost to the pharmaceutical industry. Patented high potency drug development majorly dominates the HPAPI market. The branded sector constitutes the major share of this market but the patents of this branded sector are expected to expire in the coming few years that will help HPAPI manufacturers to cater to multiple clients by producing the generic version of the ingredients in bulk.

Some of the factors driving this market at a rapid growth rate are majority of blockbuster drugs nearing patent expiry, US government promoting generic drugs to reduce its medical burden, insurance companies preferring generic drugs over patented drugs for cost effectiveness and India and China with maximum DMFs with the US FDA.

However, a large number of competitors are entering this market making it highly fragmented which may slow down the growth of this market. Moreover, reduced R&D investments leading to low demand of HPAPIs and shortage of US FDA approved manufacturing sites are also likely to be the major restraints for the growth of the high potency active pharmaceutical ingredients market.

However, North America has been the largest market for high potency pharmaceutical ingredients as the country spends highly on the development of healthcare systems, whereas the European market has experienced several fluctuations in the past few years but is expected to grow rapidly in the near future due to rise in the demand of oncology drugs in this region.

Request for customization of this report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=748

Asia Pacific region is expected to witness high growth in the coming years due to the production of generics at a significant rate. Currently, the Asia Pacific region is the second largest market after North America for HPAPIs and is expected to become the largest market soon. Skilled manpower and low labor cost are greatly contributing to API manufacturing and outsourcing combined with research and development. India and China are the major countries in the Asia Pacific region expected to witness high growth in the near future.

Some of the major players of this market are Pfizer, Roche, Novartis, GlaxoSmithkline Pharmaceuticals Ltd., BASF Se, Hospira Inc., Matrix Laboratories Limited, Covidein Plc and Astra Geneca International, among others.

This research is specially designed to estimate and analyze the demand and performance of high potency active pharmaceutical ingredients in a global scenario. The research provides in-depth analysis of the HPAPI market by end use, by application and by type segments and demand by geography. The report covers all the major product segments of the High HPAPIs market and provides in-depth analysis, historical data and statistically refined forecast for the segments covered. The study presents a comprehensive assessment of the stakeholder strategies winning imperatives for them by segmenting the HPAPI market as below:

HPAPI Market, 2012 – 2018

Introduction

HPAPI Classification as per Safebridge Consultants

Overview: HPAPI Global Market

Manufacturing Capabilities

Handling requirements
Personnel considerations
Plant & equipment
Technology

HPAPI Market, By Type of Synthesis, 2012 – 2018
Overview
Sub-Segments Of HPAPI Market
By Type Of Synthesis
Synthetic HPAPI
Biotech HPAPI
By Type of Manufacturers
Captive or In-house manufacturers
Merchant or Third party manufacturers
By Type of Market
Innovative
Generic

In addition the report provides a cross-sectional analysis of all the above segments with respect to the following geographical markets:

North America
Europe
Asia
RoW

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us

Contact

Sheela AK

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Quantum Dots Global Market Forecast 2013 - 2023

The market was valued at USD 88.5 million in 2011, which is expected to reach USD 8,246.8 million by 2023, growing at a CAGR of 53.8% from 2013 to 2023.

Browse the full Quantum Dots Market Report at http://www.transparencymarketresearch.com/quantum-dots.html

Increasing demand for energy efficient displays and lighting solutions is the major force driving the quantum dots market. In the field of electroluminescent displays, light emitting quantum dots are preferred for next generation displays as they offer improved color purity, brighter images, and energy efficiency. In addition, regulated demand from healthcare sector is expected to have positive impact on the demand of quantum dots over the forecast period. This can be attributed to the increasing use of quantum dots in wide range of medical applications including drug delivery, cell tracking, and biological imaging among others. The use of quantum dots in solar cells and VLSI (Very Large Scale Integration) design is expected to open new possibilities for quantum dots market in coming years.

Healthcare segment accounted for 77.4% of the overall revenue in 2012. However, optoelectronics segment is expected to surpass the healthcare quantum dots market, growing at the fastest CAGR of 71.5% from 2013 to 2023. Superior capabilities in terms of operating life, energy efficiency, and color quality of the emitted light make quantum dots preferred technology to be used in displays and lighting solutions. In addition, unique optical properties exhibited by quantum dots have made them attractive semiconducting material. In terms of products, the QD medical device segment held the highest market share, and was valued at approximately USD 68.5 million in 2012. The QD LED display segment is expected to grow at the highest CAGR of 85.4% from 2013 to 2023 due to tremendous growth expected in optoelectronics segment. North America was the market leader in 2012, and Asia Pacific is expected to be the fastest growing region, with an expected CAGR of 55.4% from 2013 to 2023. The growth in the region is attributed to growing demand from solar energy and optoelectronics application segments.

Request for customization of this report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1004

Major industry participants include Life Technologies Corporation (U.S.), QD Vision, Inc. (U.S.), Nanosys, Inc. (U.S.), Nanoco Technologies Ltd (U.K.), Ocean NanoTech LLC (U.S), QD Laser, Inc. (Japan), and Quantum Material Corporation (U.S.) among others. The report studies the global quantum dots market, and provides estimates in terms of revenue (USD Million) from 2013 to 2023. Market estimates on the basis of application, product type, and raw materials; have also been provided for each region. The market has been segmented as follows:

Quantum Dots Market, by Application

Health Care

Flow Cytometry
Biological imaging (in-vitro, in-vivo, and so on)
Drug Delivery
Cell Tracking
Photodynamic Theory

Browse press Release Quantum Dots Market http://www.transparencymarketresearch.com/pressrelease/quantum-dots-market.htm

Quantum Computing

Optoelectronics
Quantum Optics
Security & Surveillance
Energy

Quantum Dots Market, by Products:

QD Medical Devices
QD LED Displays
QD Lasers
QD Solar Cells
QD Chips
QD Sensors
QD Lighting

Quantum Dots Market, by Raw materials

Cadmium Selenium
Cadmium Tellurium
Non Toxic (Cadmium Free)
Others (InAs, InGaAs, PbS, and so on)
Quantum Dots Market, by Geography:

North America

Europe
Asia Pacific
Rest of the World (Latin America, Middle East and Africa)

Browse All Semiconductor & Electronics Market Research Reports @ http://www.transparencymarketresearch.com/semiconductor-market-reports-5.html

About Us

Contact

Ms. Sheela AK

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: http://www.transparencymarketresearch.com/

Sunday 28 December 2014

Smart Cards Market Forecast 2014 - 2020

Smart cards refer to IC based cards that accumulate and retrieve information using various computer systems. Smart cards consist of central processing units and different memory units. Portability of smart cards enables their extensive utilization across various applications. Smart cards primarily act as a cost-effective way to store, manage and maintain credentials for end-users.

Browse Smart Cards Market Report with Full TOC at http://www.transparencymarketresearch.com/smart-card.html

The research study titled “Smart Cards (Contact, Contactless, Dual Interface and Hybrid) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020” provides in-depth analysis of the market and related sub-segments. The report strategically focuses on market segments including different types of smart cards and their applications across various sectors. In addition, this report provides market insights and forecast about the size and growth of each segment across each of the geographic regions. The report includes detailed analysis of prevalent market trends and competitive profiles of key players. To provide better understanding of competition in the market, the report offers value chain analysis, Porter’s five forces analysis and market attractiveness analysis. The study on the global smart cards market has been conducted with the objective of providing thorough coverage of the underlying technological and socio-economic factors driving the market.

The smart cards market is expected to see consistent growth in the coming years due to the increasing demand for secure and reliable payment transactions across the retail and BFSI industry. Moreover, cost saving schemes for merchants from payments brands such as Visa, MasterCard and Europay is driving the smart card technology innovations. The decreasing prices of Subscriber Identification Module (SIM) cards and tariff rates are increasing the number of mobile subscribers, and thus further contributing to the growth of the smart cards market. However, factors such as price pressures and technological challenges along with cost of migrating to smartcard compatible readers affect the adoption of smartcards. Conversely, technology advancements, reducing prices and introduction of high-end SIMs offer potential opportunities for the growth of the smart cards market.

This report studies the current scenario as well as the future market potential for smart cards globally. The market for smart cards has been segmented based on four major parameters, namely, card type, components, applications and geography. The major types of smart cards used are contact smart cards, contactless smart cards, hybrid smart cards and dual-interface smart cards.

Request for customization of this report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=844

On the basis of components, the smart cards market is segmented as microcontroller based smart cards and memory based smart cards. The demand for microcontroller based smart cards is significantly high owing to wide adoption of such cards for contactless and dual-interface smart cards. The applications segment is classified into high-end applications and low-end applications. The high-end applications are further segmented as per its uptake across wide range of sectors including Government, Telecommunication, Transportation, Healthcare, Financial services, Retail and Loyalty, and pay TV. The market for these applications has been extensively analyzed on the basis of factors such as technology used, geographic presence and smart cards type. The market size and forecast in terms of revenue (USD million*) for each of these segments has been provided for the period 2012 to 2020, considering 2013 as the base year and 2012 as historic data. The report also provides the compounded annual growth rate (CAGR) for each segment of the market for the forecast period 2014 to 2020.

Geographically, the market for global smart cards has been segmented into four regions, namely North America, Europe, Asia Pacific and Rest of the World. The report also provides a competitive landscape, wherein the market share analysis of leading players in the global smart cards market for the year 2013, in terms of value percentage, has been discussed.

The Smart Cards Market Segmentation:

Smart Cards Market, by Type

Contact Smart Card
Contactless Smart Card
Hybrid Smart Card
Dual-interface Smart Cards

Smart Cards Market, by Components

Memory Cards
Microcontroller Cards

Smart Cards Market, by Applications

High-End Applications

Government Sector
Healthcare Sector
Transportation Sector
Telecommunications Sector
Pay TV Sector
Financial Services, Retail and Loyalty Sector

Low-End Applications

Smart Cards Market, By Geography

North America
Europe
Asia Pacific
Rest of the World (Africa, Middle East and Latin America)

Browse all Technology & Media Market Reports: http://www.transparencymarketresearch.com/technology-market-reports-8.html

About Us:

Contact:

Sheela AK

State Tower, 90 State Street,

Suite 700, Albany NY - 12207

USA/Canada Toll Free: 866-552-3453